How long did you take this medication to work?
Dosage of Roxithromycin Mekopharma in details
Adults: Recommended Dose: Mild to Moderate Acute Bacterial Exacerbations of COPD, Pneumonia of Mild Severity, Pharyngitis, Tonsillitis and Uncomplicated Skin and Skin Structure Infections: 500 mg as a single dose on the 1st day followed by 250 mg once daily on days 2 through 5.
Genital Ulcer Disease: 1000 mg as single dose.
Urethritis and Cervicitis: 2000 mg as single dose. Capsule should be given at least 1 hr before or 2 hrs after a meal. Azithromycin tablets can be taken with or without food.
Children: Use of azithromycin in children <6 months is not recommended.
What other drugs will affect Roxithromycin Mekopharma?
It is not likely that other drugs you take orally or inject will have an effect on topically applied erythromycin. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Roxithromycin Mekopharma interactions
Roxithromycin Mekopharma has a much lower affinity for cytochrome P450 than
erythromycin, and consequently has fewer interactions. Interactions may be
observed, however, with drugs that bind to alpha-1-acid glycoprotein, e.g.
Roxithromycin Mekopharma does not appear to interact with oral contraceptives,
prednisolone, carbamazepine, ranitidine or antacids.
Theophylline. A study in normal subjects concurrently administered
Roxithromycin Mekopharma and theophylline has shown some increase in the plasma
concentration of the latter. While a change in dosage is usually not required,
patients with high levels of theophylline at commencement of treatment
should have levels monitored.
Ergot alkaloids. Reactions of ergotism with possible peripheral necrosis have
been reported after concomitant therapy of macrolides with vasoconstrictive ergot alkaloids, particularly ergotamine and dihydroergotamine. Because a
clinical interaction with Roxithromycin Mekopharma cannot be excluded, administration of
Roxithromycin Mekopharma to patients taking ergot alkaloids is contraindicated.
Disopyramide. An in vitro study has shown that Roxithromycin Mekopharma can displace
protein bound disopyramide; such an effect in vivo could result in increased
serum levels of disopyramide. Consequently, ECG and, if possible,
disopyramide serum levels should be monitored.
Terfenadine. Some macrolide antibiotics (e.g. erythromycin) may increase
serum levels of terfenadine. This can result in severe cardiovascular adverse
events, including QT prolongation, torsades de pointes and other ventricular
arrhythmias. Such a reaction has not been documented with Roxithromycin Mekopharma,
which has a much lower affinity for cytochrome P450 than erythromycin.
However, in the absence of a systematic interaction study, concomitant
administration of Roxithromycin Mekopharma and terfenadine is not recommended.
Astemizole, cisapride, pimozide. Other drugs, such as astemizole, cisapride
or pimozide, which are metabolised by the hepatic isozyme CYP3A4, have
been associated with QT interval prolongation and/or cardiac arrhythmias
(typically torsades de pointes) as a result of an increase in their serum level
subsequent to interaction with significant inhibitors of this isozyme, including
some macrolide antibacterials. Although Roxithromycin Mekopharma has no or limited ability
to complex CYP3A4 and hence to inhibit the metabolism of other drugs
processed by this isozyme, a potential for clinical interaction of Roxithromycin Mekopharma
with the above mentioned drugs cannot be either ascertained or ruled out in
confidence. Thus, concomitant administration of Roxithromycin Mekopharma and such drugs
is not recommended.
Warfarin. While no interaction was observed in volunteer studies,
Roxithromycin Mekopharma appears to interact with warfarin. Increases in prothrombin time
(international normalised ratio (INR)) have been reported in patients treated
concomitantly with Roxithromycin Mekopharma and warfarin or the related vitamin K
antagonist phenprocoumon, and severe bleeding episodes have occurred as
Digoxin and other cardiac glycosides. A study in healthy volunteers has
shown that Roxithromycin Mekopharma may increase the absorption of digoxin. This effect,
common to other macrolides, may very rarely result in cardiac glycoside
toxicity. This may be manifested by symptoms such as nausea, vomiting,
diarrhoea, headache or dizziness. Cardiac glycoside toxicity may also elicit
heart conduction and/or rhythm disorders. Consequently, in patients treated
with Roxithromycin Mekopharma and digoxin or another cardiac glycoside, ECG and, if
possible, the serum level of the cardiac glycoside should be monitored. This is
mandatory if symptoms suggesting cardiac glycoside overdosage have
Midazolam. Roxithromycin Mekopharma, like other macrolides, may increase the area
under the midazolam concentration-time curve and the midazolam half-life.
Thus, the effects of midazolam may be enhanced and prolonged in patients treated with Roxithromycin Mekopharma. There is no conclusive evidence for an interaction
between Roxithromycin Mekopharma and triazolam.
Cyclosporin. A slight increase in plasma concentrations of cyclosporin A has
been observed. This does not generally necessitate altering the usual dosage.
- FDA/SPL Indexing Data. "21KOF230FA: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "(3R,4S,5S,6R,7R,9R,10E,11S,12R,13S,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Roxithromycin Mekopharma are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Roxithromycin Mekopharma. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported frequency of useNo survey data has been collected yet
Consumer reported dosesNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology